Selling, General, and Administrative Costs: Eli Lilly and Company vs Veracyte, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals and diagnostics, understanding the financial health of companies is crucial. Eli Lilly and Company, a pharmaceutical giant, and Veracyte, Inc., a leader in genomic diagnostics, present a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Over this period, Eli Lilly's SG&A expenses have shown a steady increase, peaking in 2023 with a 16% rise from 2014. In contrast, Veracyte's expenses have surged dramatically, with a staggering 352% increase, reflecting its rapid growth and expansion in the diagnostics market. This data not only highlights the scale of operations between a well-established pharmaceutical company and a burgeoning diagnostics firm but also underscores the dynamic nature of the healthcare industry. As these companies continue to evolve, their financial strategies will be pivotal in shaping their future trajectories.